BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: BIVI) | Delayed: 1.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.37 | 52 Week High | $0.40 | |||
| Open | $1.37 | 52 Week Low | $0.17 | |||
| Day High | $1.37 | P/E | N/A | |||
| Day Low | $1.37 | EPS | $0.00 | |||
| Volume | 7 | |||||
